Mechanisms linking the frail sarcomere to noncompaction cardiomyopathy
Funded at Icahn School of Medicine at Mount Sinai · NIH-11468167 · Data updated 2026-11-12
This grant studies how changes in a heart muscle protein called MYH7 may lead to a form of heart disease called left ventricular noncompaction, using patient-derived stem cells and lab-made heart tissues.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 14, 2026 |
| Project end | April 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $249,000 |
| NIH project number | 4R00HL168239-03 |
| Project ID | NIH-11468167 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with MYH7-related LVNC or related cardiomyopathies and those contributing cells or samples for iPSC-based studies.
✕Less likely to help
Patients without LVNC or MYH7-related disease may not directly benefit from this research.
What this research studies
Researchers will use stem cells taken from people and turn them into heart tissue to see how specific MYH7 gene changes affect heart muscle function and structure. They will compare truncation and missense variants to understand why some people develop noncompaction cardiomyopathy. The study also aims to help classify gene variants of uncertain significance to better guide future diagnosis and treatment. This is done within a structured training program to develop expertise in cardiac disease modeling.
Why it matters
Potential benefit: If successful, this work could improve diagnosis and pave the way for targeted therapies for patients with LVNC linked to MYH7 variants.
How similar studies have gone: Prior research shows MYH7 variants are linked to cardiomyopathy and stem-cell models can reveal how these variants affect heart cells, but more work is needed to translate findings to patients.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Monroe, Tanner O — Icahn School of Medicine at Mount Sinai
- Study coordinator: Monroe, Tanner O
Related research
Other NIH-funded projects on the same topics.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
-
Global bromocriptine trial to help postpartum heart failure patients
A large international trial tests whether adding bromocriptine to standard heart failure treatment improves outcomes for new mothers with a specific pregnancy-related heart condition.
-
Global Bromocriptine Trial to Help Postpartum Heart Failure
A large international study will test whether adding bromocriptine to standard heart failure treatment helps women with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.